Finanzen von Cellyan Biotechnology Co Ltd (HKPD)HKPDCellyan Biotechnology Co Ltd

Evaluating the bottom line, Cellyan Biotechnology Co Ltd maintains a gross margin of 10.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7.47%, while the net margin is -8.46%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HKPD converts its operational activities into shareholder value.

The financial performance shows a declining trend with a gross margin of only 10.32% in the latest quarter and a negative net margin of -8.46% projected for Q4 2026. The current ratio is healthy at 3.86, indicating good short-term financial stability, but the overall profitability metrics are concerning.